Guy Leverger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Guy Leverger has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
G Schaison
Department of Paediatric Haematology, Saint-Louis Hospital, 75010 Paris, France
18 shared publications- Anne Auvrignon
Department of Pediatric Hematology and Oncology, Trousseau Hospital (AP-HP), 75012, Paris, France.
5 shared publications J Landman-Parker
5 shared publicationsA Baruchel
Department of Paediatric Haematology, Saint-Louis Hospital, 75010 Paris, France
4 shared publicationsA Bancillon
3 shared publications- Arnaud Petit
Hôpital Armand Trousseau, APHP Sorbonne Université Paris France
3 shared publications
Latest Publications
- 24 April 2015
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 174 (10) , 1399-1403
Childhood diagnosis of genetic thrombocytopenia with mutation in the ankyrine repeat domain 26 gene
The most common diagnosis for pediatric thrombocytopenia is immune thrombocytopenia. Nevertheless, in atypical cases, the hypothesis of an inherited thrombocytopenia has to be investigated. We report a series of cases of a newly described entity, genetic thrombocytopenia with mutation in the ankyrine 26 gene, diagnosed from the exploration of five pediatric cases of thrombocytopenia. This entity is characterized by a moderate thrombocytopenia with normal mean platelet volume, and poorly bleeding. Its transmission is autosomal dominant. Final diagnosis is made by sequencing of a short DNA region of ANKRD26 gene. This pathology can be considered as an hematological malignancy predisposition syndrome. Conclusion: We report the first cohort of pediatric patients diagnosed with thrombocytopenia with mutation in the ankyrine 26. The aim is to underline the specificities of this entity in children and bring it to the knowledge of pediatricians who may be in first place to manage these patients.
- 24 April 2015
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 174 (10) , 1399-1403
Childhood diagnosis of genetic thrombocytopenia with mutation in the ankyrine repeat domain 26 gene
The most common diagnosis for pediatric thrombocytopenia is immune thrombocytopenia. Nevertheless, in atypical cases, the hypothesis of an inherited thrombocytopenia has to be investigated. We report a series of cases of a newly described entity, genetic thrombocytopenia with mutation in the ankyrine 26 gene, diagnosed from the exploration of five pediatric cases of thrombocytopenia. This entity is characterized by a moderate thrombocytopenia with normal mean platelet volume, and poorly bleeding. Its transmission is autosomal dominant. Final diagnosis is made by sequencing of a short DNA region of ANKRD26 gene. This pathology can be considered as an hematological malignancy predisposition syndrome. Conclusion: We report the first cohort of pediatric patients diagnosed with thrombocytopenia with mutation in the ankyrine 26. The aim is to underline the specificities of this entity in children and bring it to the knowledge of pediatricians who may be in first place to manage these patients.
- 31 May 2011
- Published by Elsevier in Archives de Pédiatrie
- Vol. 18, S33-S41
Les échinocandines chez l’enfant Echinocandins in children
- 31 May 2011
- Published by Elsevier in Archives de Pédiatrie
- Vol. 18, S33-S41
Les échinocandines chez l’enfant Echinocandins in children
- 1 May 2011
- Published by Elsevier in Archives de Pédiatrie
- Vol. 18 (5) , H242-H243
« Est-ce que les doudous vont au ciel ? » [1]
- 1 May 2011
- Published by Elsevier in Archives de Pédiatrie
- Vol. 18 (5) , H242-H243
« Est-ce que les doudous vont au ciel ? » [1]
- 31 December 2010
- Published by Elsevier in Archives de Pédiatrie
- Vol. 17 (12) , 1637-1644
Existe-t-il un risque de déficit corticotrope au décours du traitement d’induction d’une leucémie aiguë lymphoblastique ?
- 31 December 2010
- Published by Elsevier in Archives de Pédiatrie
- Vol. 17 (12) , 1637-1644
Existe-t-il un risque de déficit corticotrope au décours du traitement d’induction d’une leucémie aiguë lymphoblastique ?
- 31 August 2010
- Published by Elsevier in Archives de Pédiatrie
- Vol. 17 (8) , 1185-1191
Les thrombopénies génétiques
- 31 August 2010
- Published by Elsevier in Archives de Pédiatrie
- Vol. 17 (8) , 1185-1191
Les thrombopénies génétiques
- 1 October 2009
- Vol. 193 (7) , 1495
[A brief history of treatments for childhood acute lymphoblastic leukaemia].
Acute lymphoblastic leukaemia is the most frequent childhood malignancy. The first effective drugs, which provided only short-lived complete remission, started to be used in the 1950s. All the effective drugs currently in use were discovered in the 1960s, when the first multidrug chemotherapy regimens were shown to confer prolonged complete remission, raising the possibility of a cure. Simultaneously, progress in our knowledge of leukaemic cells, and the identification of prognostic factors such as leukocytosis, age, cytogenetic and molecular abnormalities, and the early therapeutic response of leukaemic cells, led to randomized multicenter national and international trials. As a result, the chance of cure increased gradually over the last three decades. In rich countries, the overall survival rate among children with acute lymphoblastic leukaemia now reaches 85 to 90%.
- 1 October 2009
- Vol. 193 (7) , 1495
[A brief history of treatments for childhood acute lymphoblastic leukaemia].
Acute lymphoblastic leukaemia is the most frequent childhood malignancy. The first effective drugs, which provided only short-lived complete remission, started to be used in the 1950s. All the effective drugs currently in use were discovered in the 1960s, when the first multidrug chemotherapy regimens were shown to confer prolonged complete remission, raising the possibility of a cure. Simultaneously, progress in our knowledge of leukaemic cells, and the identification of prognostic factors such as leukocytosis, age, cytogenetic and molecular abnormalities, and the early therapeutic response of leukaemic cells, led to randomized multicenter national and international trials. As a result, the chance of cure increased gradually over the last three decades. In rich countries, the overall survival rate among children with acute lymphoblastic leukaemia now reaches 85 to 90%.
- Open Access
- 13 January 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 14
Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study
We explored the heterogeneity of philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1-ALL) in a study of the effect of early features on prognosis in children. Here we report the long-term results of the FRALLE 93 study conducted in the era before the use of tyrosine kinase inhibitors. Between 1993 and 1999, 36 children with Ph1-ALL were enrolled into the FRALLE 93 protocol. After conventional four-drug induction, children were stratified by availability of an HLA-matched sibling. Complete remission (CR) was observed in 26 children (72%), of which 13 underwent allogeneic bone marrow transplantation (BMT). Thirty-one children were good responders to prednisone, defined on day 8, and 21 were good responders to chemotherapy, defined by day-21 bone marrow (M1). Overall five-year disease-free survival (DFS) was 42 ± 9.7%. Based on multivariate analysis, two groups showed marked differences in five-year outcome: children with age3 and day-21 M1 marrow had a more favorable prognosis (14 pts: 100% CR, event free survival [EFS]: 57%, overall survival [OS]: 79%), than the high-risk group (22 patients: 55% CR, EFS: 18%, OS: 27%) (p < 0.005). We also observed a non statistically significant difference (p = 0.14) in outcome between these groups for transplanted patients (5-year DFS: 83 ± 14% and 33 ± 15%, respectively). Age, leukocyte count and early response to treatment defined by the D21 bone marrow response provide an accurate model for outcome prediction. The combination of available tools such as minimal residual disease assessment with determination of these simple factors could be useful for refining indications for BMT in the current era of tyrosine-kinase inhibitor-based therapy.
- 13 January 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 14
Open AccessImpact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study
We explored the heterogeneity of philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1-ALL) in a study of the effect of early features on prognosis in children. Here we report the long-term results of the FRALLE 93 study conducted in the era before the use of tyrosine kinase inhibitors. Between 1993 and 1999, 36 children with Ph1-ALL were enrolled into the FRALLE 93 protocol. After conventional four-drug induction, children were stratified by availability of an HLA-matched sibling. Complete remission (CR) was observed in 26 children (72%), of which 13 underwent allogeneic bone marrow transplantation (BMT). Thirty-one children were good responders to prednisone, defined on day 8, and 21 were good responders to chemotherapy, defined by day-21 bone marrow (M1). Overall five-year disease-free survival (DFS) was 42 ± 9.7%. Based on multivariate analysis, two groups showed marked differences in five-year outcome: children with age3 and day-21 M1 marrow had a more favorable prognosis (14 pts: 100% CR, event free survival [EFS]: 57%, overall survival [OS]: 79%), than the high-risk group (22 patients: 55% CR, EFS: 18%, OS: 27%) (p < 0.005). We also observed a non statistically significant difference (p = 0.14) in outcome between these groups for transplanted patients (5-year DFS: 83 ± 14% and 33 ± 15%, respectively). Age, leukocyte count and early response to treatment defined by the D21 bone marrow response provide an accurate model for outcome prediction. The combination of available tools such as minimal residual disease assessment with determination of these simple factors could be useful for refining indications for BMT in the current era of tyrosine-kinase inhibitor-based therapy.
- 31 December 2007
- Published by Elsevier in Thrombosis Research
- Vol. 120, S174
PO-91 Venous thromboses in children treated for acute lymphoblastic leukaemia (FRALLE 2000)
- 31 December 2007
- Published by Elsevier in Thrombosis Research
- Vol. 120, S174
PO-91 Venous thromboses in children treated for acute lymphoblastic leukaemia (FRALLE 2000)
- 5 October 2007
- Vol. 65 (5) , 569-73
[Transient myeloproliferative disorder in a neonate without Down syndrome].
We report a new case of transient myeloproliferative disorder (TMD) in a non Down syndrome neonate. The cytogenetic and molecular studies within from the blood blast cells identified a trisomy 21 and a partial deletion in exon 2 of the transcription factor GATA1. Spontaneous regression of the TMD was achieved at the age of 1 month as the clonal and molecular abnormalities. A survey by periodic cytological examinations of peripheral blood cells and GATA1 mutation analysis was instituted since three years and has not detected up to date acute leukaemia.
- 5 October 2007
- Vol. 65 (5) , 569-73
[Transient myeloproliferative disorder in a neonate without Down syndrome].
We report a new case of transient myeloproliferative disorder (TMD) in a non Down syndrome neonate. The cytogenetic and molecular studies within from the blood blast cells identified a trisomy 21 and a partial deletion in exon 2 of the transcription factor GATA1. Spontaneous regression of the TMD was achieved at the age of 1 month as the clonal and molecular abnormalities. A survey by periodic cytological examinations of peripheral blood cells and GATA1 mutation analysis was instituted since three years and has not detected up to date acute leukaemia.
- 30 June 2006
- Published by Elsevier in Archives de Pédiatrie
- Vol. 13 (6) , 621-623
État des lieux, besoins et ressources en soins palliatifs pédiatriques
- 30 June 2006
- Published by Elsevier in Archives de Pédiatrie
- Vol. 13 (6) , 621-623
État des lieux, besoins et ressources en soins palliatifs pédiatriques